IMMUNOME INC (IMNM)
US45257U1088 - Common Stock
Overall IMNM gets a fundamental rating of 3 out of 10. We evaluated IMNM against 568 industry peers in the Biotechnology industry. While IMNM has a great health rating, there are worries on its profitability. IMNM is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year IMNM has reported negative net income.
In the past year IMNM has reported a negative cash flow from operations.
In the past 5 years IMNM always reported negative net income.
In the past 5 years IMNM always reported negative operating cash flow.
1.2 Ratios
IMNM has a worse Return On Assets (-118.86%) than 79.82% of its industry peers.
IMNM has a worse Return On Equity (-142.08%) than 63.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -118.86% | ||
| ROE | -142.08% | ||
| ROIC | N/A |
ROA(3y)-90.19%
ROA(5y)-103.39%
ROE(3y)-121.9%
ROE(5y)-145.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for IMNM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IMNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IMNM has more shares outstanding
IMNM has more shares outstanding than it did 5 years ago.
There is no outstanding debt for IMNM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
IMNM has an Altman-Z score of 7.07. This indicates that IMNM is financially healthy and has little risk of bankruptcy at the moment.
IMNM has a better Altman-Z score (7.07) than 83.72% of its industry peers.
IMNM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.07 |
ROIC/WACCN/A
WACC11.91%
2.3 Liquidity
IMNM has a Current Ratio of 6.17. This indicates that IMNM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.17, IMNM is in the better half of the industry, outperforming 62.12% of the companies in the same industry.
A Quick Ratio of 6.17 indicates that IMNM has no problem at all paying its short term obligations.
IMNM has a Quick ratio of 6.17. This is in the better half of the industry: IMNM outperforms 62.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.17 |
3. Growth
3.1 Past
IMNM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -234.92%.
IMNM shows a decrease in Revenue. In the last year, the revenue decreased by -0.60%.
EPS 1Y (TTM)-234.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-117.31%
Revenue 1Y (TTM)-0.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-18.49%
3.2 Future
The Earnings Per Share is expected to grow by 10.12% on average over the next years. This is quite good.
The Revenue is expected to grow by 78.88% on average over the next years. This is a very strong growth
EPS Next Y-333.17%
EPS Next 2Y-75.16%
EPS Next 3Y-45.31%
EPS Next 5Y10.12%
Revenue Next Year-23.42%
Revenue Next 2Y-44.86%
Revenue Next 3Y14.82%
Revenue Next 5Y78.88%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
IMNM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMNM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as IMNM's earnings are expected to decrease with -45.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-75.16%
EPS Next 3Y-45.31%
5. Dividend
5.1 Amount
IMNM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IMMUNOME INC
NASDAQ:IMNM (12/20/2024, 8:18:24 PM)
After market: 10.97 0 (0%)10.97
-0.11 (-0.99%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners80.18%
Inst Owner Change7.77%
Ins Owners1.75%
Ins Owner Change5.43%
Market Cap684.75M
Analysts87.69
Price Target30.6 (178.94%)
Short Float %18.89%
Short Ratio12.89
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-19.89%
Min EPS beat(2)-22.13%
Max EPS beat(2)-17.65%
EPS beat(4)0
Avg EPS beat(4)-413.67%
Min EPS beat(4)-1360.22%
Max EPS beat(4)-17.65%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)12.31%
Min Revenue beat(2)-9.11%
Max Revenue beat(2)33.73%
Revenue beat(4)2
Avg Revenue beat(4)10.47%
Min Revenue beat(4)-63.97%
Max Revenue beat(4)81.24%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.98%
PT rev (3m)-6.98%
EPS NQ rev (1m)-40.12%
EPS NQ rev (3m)-40.12%
EPS NY rev (1m)-3.12%
EPS NY rev (3m)-3.12%
Revenue NQ rev (1m)17.74%
Revenue NQ rev (3m)17.74%
Revenue NY rev (1m)11.81%
Revenue NY rev (3m)11.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 67.6 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.19 | ||
| P/tB | 3.19 | ||
| EV/EBITDA | N/A |
EPS(TTM)-7.89
EYN/A
EPS(NY)-3.04
Fwd EYN/A
FCF(TTM)-2.22
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS0.16
BVpS3.44
TBVpS3.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -118.86% | ||
| ROE | -142.08% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-90.19%
ROA(5y)-103.39%
ROE(3y)-121.9%
ROE(5y)-145.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 4152.22% | ||
| Cap/Sales | 518.16% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.17 | ||
| Altman-Z | 7.07 |
F-Score3
WACC11.91%
ROIC/WACCN/A
Cap/Depr(3y)83.96%
Cap/Depr(5y)73.32%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-234.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-117.31%
EPS Next Y-333.17%
EPS Next 2Y-75.16%
EPS Next 3Y-45.31%
EPS Next 5Y10.12%
Revenue 1Y (TTM)-0.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-18.49%
Revenue Next Year-23.42%
Revenue Next 2Y-44.86%
Revenue Next 3Y14.82%
Revenue Next 5Y78.88%
EBIT growth 1Y-392.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-839.53%
EBIT Next 3Y-86.37%
EBIT Next 5YN/A
FCF growth 1Y-378.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-199.07%
OCF growth 3YN/A
OCF growth 5YN/A